|Bid||0.00 x 800|
|Ask||12.50 x 800|
|Day's Range||11.00 - 11.80|
|52 Week Range||7.01 - 22.96|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 10, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||18.17|
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
CAMBRIDGE, Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in the following virtual investor conferences: * Stifel Virtual 2020 Healthcare Conference Presentation on Wednesday, November 18, 2020 at 11:20 a.m. ET. * Piper Sandler 32nd Annual Virtual Healthcare Conference Prerecorded Fireside Chat Available on Monday, November 23, 2020 at 10:00 a.m. ETAudio webcasts of the presentations will be available through the Investor Relations section of the Fulcrum website at https://ir.fulcrumtx.com/events-and-presentations. Archived replays will be available on the Company’s website for 90 days after each conference.About Fulcrum Therapeutics Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s proprietary product engine identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The company has advanced losmapimod to Phase 2 clinical development for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and Phase 3 for the treatment of COVID-19. Fulcrum has also advanced FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and beta thalassemia into Phase 1 clinical development.Please visit www.fulcrumtx.com.Contact: Christi Waarich Director, Investor Relations and Corporate Communications 617-651-8664 email@example.com
Novavax's (NVAX) bottom line deteriorates year over year in the third quarter of 2020. Revenues fall shy of estimates as well. Stock dips in after-hours trading.